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L E T T E R  T O  T H E  E D I T O R
Autosomal dominant macrothrombocytopenia caused by a rare 
GPIBB variant: The importance of DNA sequencing
Dear editors,
We have read with great interest the article by Hayward et al1 on 
diagnostic testing for platelet function disorders (PFD). Concerning 
molecular genetic testing, classified as third-step laboratory tests in 
the most recent International Society on Thrombosis and Haemostasis 
(ISTH) guideline,2 a survey among 123 diagnostic laboratories re-
vealed that only 12%-16% of participants perform these kind of tests. 
In this light, it was stated that DNA sequencing techniques have an 
overall low diagnostic yield, unless a specific disorder is suspected 
from the clinical picture.1 Screening for rare disorders in all patients 
with suspected PFD would pose an important financial burden on 
patients and healthcare authorities. We fully agree with the authors 
on this point; however, we would like to emphasize the added value 
genetic testing may have in specific cases by presenting two patients 
in which DNA sequencing was paramount in assessing a correct di-
agnosis of PFD and identifying the underlying cause of macrothrom-
bocytopenia associated with variable bleeding tendency. All testing 
described in this report was performed for diagnostic purposes.
Two unrelated patients were both referred to a hematologist for 
diagnostic elaboration of mild macrothrombocytopenia, persistently 
found in routine peripheral blood analyses. The first patient was a 
32-year-old woman. Her medical history revealed multiple bleeding 
symptoms, such as frequent ecchymoses, gingival bleeding, metror-
rhagia, and bright red blood loss per rectum. She presented with an 
ISTH-bleeding assessment tool (BAT) score of 7 at the time of first 
consultation.3 The second patient, a 22-year-old man, had no docu-
mented bleeding diathesis. Both patients did not report to take any 
drugs potentially interfering with platelet function. Family history 
revealed that the mother of the first patient and the father of the 
second patient also had macrothrombocytopenia, without apparent 
bleeding symptoms.
Complete blood counts, determined on Sysmex hematology an-
alyzers, showed moderate thrombocytopenia, which already per-
sisted for several years in both patients (patient one, 95-141 x 109 
platelets/L; patient two, 88-103 x 109 platelets/L), along with in-
creased platelet volume (patient one, mean platelet volume 12.9-
14.0 fL) or platelet anisocytosis (patient two, multiple large platelets 
on blood smear) and elevated immature platelet fractions (patient 
one, 15.4%-17.0%; patient two, 23.4%-29.5%). Of note, routine co-
agulation assays (PT, aPTT, and fibrinogen) were normal for both 
patients. Factor VIII coagulant activity and von Willebrand factor 
(VWF) screening tests (antigen and ristocetin cofactor activity) were 
determined for the female patient only and were normal as well. The 
presence of large platelets, mildly reduced platelet counts, positive 
family history, and a bleeding diathesis, at least in one patient, led 
to the suspicion of the presence of a congenital platelet disorder, 
such as Bernard-Soulier syndrome (BSS). As no syndromic features 
and no structural abnormalities in platelets (other than increased 
volume and anisocytosis), erythrocytes, or leukocytes were noticed, 
in vitro platelet aggregation and expression of the glycoprotein (GP) 
IB-IX-V receptor on platelets were evaluated, according to ISTH 
recommendations.2
LTA was performed according to the guidelines4 on a Chrono-
Log® 700 lumiaggregometer (Chrono-log corporation), yielding 
normal results with all tested agonists for both patients. Maximal 
aggregation with 1.5 mg/mL ristocetin, being an important diagnos-
tic test in BSS, was 93%-99%. In addition to LTA, a lumiaggregom-
etry-based ATP-release assay using thrombin (1 U/mL) as agonist 
was performed on the Chrono-Log® 700, yielding a clearly reduced 
result for patient one (ATP-release 0.3 nmol, local cutoff 0.5 nmol) 
and absent ATP-release for patient two. The latter result could not 
be confirmed, as no second sample was available. To exclude δ-stor-
age pool disease, platelet electron microscopy was subsequently 
performed on a Zeis EM900 transmission electron microscope (Carl 
Zeis). Normal platelet dense granule content was found for patient 
one, while an inconclusive result was obtained for patient two due 
to low platelet numbers in fixed platelet preparations. Consequently, 
presence of a storage pool disorder could not be fully excluded for 
the latter patient. Evaluation of the expression of the GP Ib-IX-V 
receptor complex on platelet surface was performed by flow cy-
tometric detection of CD42b, being the α-subunit of GPIb, using a 
FACSCantoTM II flow cytometer (BD). Slightly reduced GPIb expres-
sion was found for patient two only (CD42b mean fluorescent in-
tensity (MFI) 67%, expressed as % to control), while it was normal in 
patient one (CD42b MFI 90%).
As the above mentioned analyses could not provide a clear ex-
planation for the existing macrothrombocytopenia and variable 
bleeding tendency, high-throughput DNA sequencing for inherited 
platelet disorders was performed using the ThromboGenomics di-
agnostic platform.5 DNA sequencing revealed the presence of a 
heterozygous c.47T > C variant (p.Leu16Pro) in GP1BB, the gene en-
coding the GPIbβ-subunit of the GP Ib-IX-V receptor. This missense 
mutation has recently been associated with autosomal dominant 
macrothrombocytopenia and monoallelic BSS,6,7 as discussed below.
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The platelet transmembrane GP Ib-IX-V receptor complex plays 
an essential role during the initial steps of primary hemostasis by ad-
hering platelets to damaged subendothelium via VWF. A variety of 
mutations in GP1BA, GP1BB, and GP9, the genes encoding the GPIbα, 
GPIbβ, and GPIX subunits, respectively, have been identified to 
cause BSS when present in homozygous or compound heterozygous 
condition. In its classical from, BSS is inherited in an autosomal re-
cessive way (biallelic BSS) and in vitro ristocetin-induced platelet ag-
gregation and GP Ib-IX-V expression are absent or strongly reduced, 
enabling diagnosis based on LTA and flow cytometry in most cases. 
Rare monoallelic mutations in GP1BA and GP1BB may cause an au-
tosomal dominant form of BSS, usually characterized by mild macro-
thrombocytopenia and less severe or absent bleeding tendency.6,8,9
The c.47T >C variant in the GP1BB gene results in a missense 
variant p.Leu16Pro. This variant is absent from the population da-
tabase gnomAD.10 Leu16Pro is located in the signal peptide and is 
predicted to interfere with SEC61-mediated secretion and/or signal 
peptide removal, but secretion studies for this variant were not per-
formed.8 Pathogenicity scoring for the c.47T >C variant supports 
a deleterious defect (SIFT 0.01 and CADD 22.50). According to 
the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology variant classification guide-
lines,11 this variant can be classified as a likely pathogenic variant 
(PM2, PS4, and PP4). The c.47T >C variant has previously been seen 
in three unrelated index cases with mild macrothrombocytopenia 
with cosegregation data in the affected parent that also carries the 
variant.6,7 Sivapalaratnam et al described three cases originating 
from two families presenting with normal or slightly reduced platelet 
counts and increased platelet volume. Abnormal platelet agglutina-
tion to ristocetin was found in 2/3 patients. Mildly reduced GPIb 
expression was reported for the two related patients, while data for 
the third patient were not available. The authors mentioned bleed-
ing in both cases without further details.6 Babuty et al described 
two related patients (father and son) carrying the same mutation. 
They both had moderate macrothrombocytopenia and high imma-
ture platelet fraction. Reduced, albeit mild, GPIb expression in plate-
lets was found, together with impaired ristocetin-induced platelet 
aggregation. The father showed various bleeding symptoms, includ-
ing frequent bruising, epistaxis, gingival bleeding, and postoperative 
hematoma. No increased bleeding tendency was noticed in his son.7
Interestingly, while mild macrothrombocytopenia was a constant 
finding in nearly all cases carrying the monoallelic c.47T >C mutation 
in GPIBB, heterogeneity in in vitro platelet aggregation response to 
ristocetin and platelet GPIb expression seems to exist. In contrast to 
the previously described cases, our patients showed normal platelet 
aggregation to ristocetin and slightly reduced expression of GPIb on 
platelets was found in one patient only. In addition to the variable 
bleeding tendency, this may illustrate the variable biological pheno-
type of patients carrying this mutation. The cohort study presented 
by Sivapalaratnam et al showed that clinical and laboratory findings 
for dominant forms of macrothrombocytopenia are indeed highly 
variable.6 Cosegregation studies would support the genotype-phe-
notype correlation for our cases; however, we did not have access to 
samples from pedigrees. Concerning the possibility of other factors 
underlying the macrothrombocytopenia, it should be noted that all 
genes currently known for macrothrombocytopenia were evaluated 
in our patients using the ThromboGenomics gene panel test5 and 
no other variants were found that could modify the phenotype. 
However, noncoding variants and/or variants in novel other genes 
cannot be excluded as modifiers. The variable phenotype may pose 
a challenge to diagnostic algorithms solely based on LTA and flow cy-
tometry. If mutation analysis would not have been included in the di-
agnostic work-up, our patients would not have received an adequate 
diagnosis. This would have put them at risk of being misdiagnosed 
with immune thrombocytopenia. In this light, it could be interesting 
to evaluate in further research how many cases with macrothrom-
bocytopenia would need to be sequenced to find a pathogenic 
variant. Downes et al5 found that approximately 50% of thrombo-
cytopenia patients remained without a genetic diagnosis using the 
ThromboGenomics gene panel test; however, this cohort was not 
separated into thrombocytopenia versus macrothrombocytopenia.
In conclusion, the presented cases highlight the value of muta-
tion analysis when congenital macrothrombocytopenia is suspected, 
as platelet aggregation assays and flow cytometric detection of GP 
Ib-IX-V expression might not be sufficient to detect monoallelic BSS 
subtypes, in contrast to classical biallelic BSS.
ACKNOWLEDG EMENTS
Laboratory analyses were performed under the supervision of 
Katrien M. J. Devreese, Jan Dierick, Ariane Luyckx, and Kathleen 
Freson. Anna Vantilborgh and Sarah Debussche were responsible 
for patient examination and management as clinical hematologists. 
Pieter M. De Kesel and Katrien M. J. Devreese wrote the manuscript. 
Kathleen Freson cowrote the manuscript concerning data on DNA 
sequencing. Katrien M. J. Devreese, Kathleen Freson, Jan Dierick, 
Anna Vantilborgh, Ariane Luyckx, and Sarah Debussche revised the 
manuscript critically. All authors approved the final version of the 
manuscript.
CONFLIC T OF INTERE S TS
The authors have no competing interests.
Pieter M. De Kesel1
Anna Vantilborgh2
Jan Dierick3
Ariane Luyckx3
Sarah Debussche4
Kathleen Freson5
Katrien M. J. Devreese1
1Department of Laboratory Medicine, Ghent University 
Hospital, Ghent, Belgium
2Department of Hematology, Ghent University Hospital, Ghent, 
Belgium
3Department of Laboratory Medicine, AZ Maria Middelares, 
Ghent, Belgium
     |  3LETTER TO THE EDITOR
4Department of Hematology, AZ Maria Middelares, Ghent, 
Belgium
5Department of Cardiovascular Sciences, Center for Molecular 
and Vascular Biology, University of Leuven, Leuven, Belgium
Correspondence
Katrien M.J. Devreese, Coagulation Laboratory, Department 
of Laboratory Medicine, Ghent University Hospital, Corneel 
Heymanslaan 10, 9000 Ghent, Belgium.
Email: Katrien.Devreese@uzgent.be
ORCID
Pieter M. De Kesel  https://orcid.org/0000-0002-6975-6194 
R E FE R E N C E S
 1. Hayward CP, Moffat KA, Brunet J, et al. Update on diagnostic test-
ing for platelet function disorders: what is practical and useful? Int J 
Lab Hematol. 2019;41:26-32.
 2. Gresele P. Subcommittee on Platelet Physiology of the International 
Society on Thrombosis and Hemostasis. Diagnosis of inherited 
platelet function disorders: guidance from the SSC of the ISTH. J 
Thromb Haemost. 2015;13:314-322.
 3. Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assess-
ment tool: a standardized questionnaire and a proposal for a new 
bleeding score for inherited bleeding disorders. J Thromb Haemost. 
2010;8:2063-2065.
 4. Hayward CP, Moffat KA, Raby A, et al. Development of North 
American consensus guidelines for medical laboratories that per-
form and interpret platelet function testing using light transmission 
aggregometry. Am J Clin Pathol. 2010;134:955-963.
 5. Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput 
sequencing of 2,396 patients with bleeding, thrombotic and plate-
let disorders. Blood. 2019. https ://doi.org/10.1182/blood.20188 
91192 .
 6. Sivapalaratnam S, Westbury SK, Stephens JC, et al. Rare variants in 
GP1BB are responsible for autosomal dominant macrothrombocy-
topenia. Blood. 2017;129:520-524.
 7. Babuty A, Boisseau P, Eveillard M, et al. A new case of heterozygous 
variant of the GP1BB gene responsible for macrothrombocytope-
nia. Br J Haematol. 2019;186:157-159.
 8. Savoia A, Kunishima S, De Rocco D, et al. Spectrum of mutations in 
Bernard-Soulier Syndrome. Hum Mutat. 2014;35:1033-1045.
 9. Balduini CL, Savoia A. Genetics of familial forms of thrombocytope-
nia. Hum Genet. 2012;131:1821–1832.
 10. Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 
human exomes and genomes reveals the spectrum of loss-of-func-
tion intolerance across human protein-coding genes. bioRxiv. 2019. 
https ://doi.org/10.1101/531210.
 11. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the 
interpretation of sequence variants: a joint consensus recom-
mendation of the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology. Genet Med. 
2015;17:405-424.
